PTPA and cancer: Moreover, point mutations or deletions of PPP2R1B were found to disrupt the binding of PP2Ac with PP2Aaβ in CRC patient tissues contributing to the deregulation of PP2A in CRC, though the frequency of PPP2R1B mutations in cancers is low [28, 32].